BMS-265246 is primarily utilized in research and development within the pharmaceutical industry, particularly in the study of cancer therapeutics. It functions as a selective inhibitor of cyclin-dependent kinase 1 (CDK1), which plays a critical role in cell cycle regulation. By inhibiting CDK1, this compound helps researchers investigate the mechanisms of cell cycle arrest and apoptosis in cancer cells. Its application extends to preclinical studies aimed at understanding the potential of CDK1 inhibition as a strategy for cancer treatment. Additionally, BMS-265246 is used in biochemical assays to explore the broader implications of CDK inhibition in various cellular processes, contributing to the development of targeted cancer therapies.